DCF Advisers LLC Acquires 17,000 Shares of Pfizer Inc. (NYSE:PFE)

DCF Advisers LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 49.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,350 shares of the biopharmaceutical company's stock after buying an additional 17,000 shares during the quarter. DCF Advisers LLC's holdings in Pfizer were worth $1,362,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer during the 4th quarter worth about $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the 4th quarter valued at about $28,000. Noble Wealth Management PBC bought a new position in shares of Pfizer in the fourth quarter worth about $31,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $32,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on PFE shares. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group dropped their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Citigroup reduced their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and an average target price of $31.92.

Remove Ads

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by insiders.

Pfizer Trading Down 0.6 %

NYSE:PFE traded down $0.15 on Monday, reaching $26.13. The company's stock had a trading volume of 37,863,216 shares, compared to its average volume of 36,651,022. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The business's 50-day moving average price is $26.17 and its two-hundred day moving average price is $27.04. The firm has a market cap of $148.21 billion, a PE ratio of 18.53, a PEG ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.10 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.